相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。DoseCal: a virtual calculator for dosage conversion between human and different animal species
P. Janhavi et al.
ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY (2022)
Ponatinib, Lestaurtinib, and mTOR/PI3K Inhibitors Are Promising Repurposing Candidates against Entamoeba histolytica
Monica M. Kangussu-Marcolino et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)
One health therapeutics: Target-Based drug development for cryptosporidiosis and other apicomplexa diseases
Wesley C. Van Voorhis et al.
VETERINARY PARASITOLOGY (2021)
A Curious Case for Development of Kinase Inhibitors as Antigiardiasis Treatments Using Advanced Drug Techniques
Samantha A. Michaels et al.
ACS INFECTIOUS DISEASES (2021)
Efficacy and Tolerability of Quinacrine Monotherapy and Albendazole Plus Chloroquine Combination Therapy in Nitroimidazole-Refractory Giardiasis: A TropNet Study
Andreas Neumayr et al.
CLINICAL INFECTIOUS DISEASES (2021)
Methionyl-tRNA synthetase inhibitor has potent in vivo activity in a novel Giardia lamblia luciferase murine infection model
Samantha A. Michaels et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
High-Throughput Screening of the ReFRAME Library Identifies Potential Drug Repurposing Candidates for Trypanosoma cruzi
Jean A. Bernatchez et al.
MICROORGANISMS (2020)
Anti-Giardia Drug Discovery: Current Status and Gut Feelings
Andrew Riches et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer
Ayesha Murtuza et al.
CANCER RESEARCH (2019)
The ReFRAME library as a comprehensive drug repurposing library to identify mammarenavirus inhibitors
Yu-Jin Kim et al.
ANTIVIRAL RESEARCH (2019)
Identification of plicamycin, TG02, panobinostat, lestaurtinib, and GDC-0084 as promising compounds for the treatment of central nervous system infections caused by the free-living amebae Naegleria, Acanthamoeba and Balamuthia
Monica M. Kangussu-Marcolino et al.
INTERNATIONAL JOURNAL FOR PARASITOLOGY-DRUGS AND DRUG RESISTANCE (2019)
Screening of the Pathogen Box for inhibitors with dual efficacy against Giardia lamblia and Cryptosporidium parvum
Kelly M. Hennessey et al.
PLOS NEGLECTED TROPICAL DISEASES (2018)
The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosis
Jeff Janes et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Treatment-refractory giardiasis: challenges and solutions
Marco Lalle et al.
INFECTION AND DRUG RESISTANCE (2018)
Bumped-Kinase Inhibitors for Cryptosporidiosis Therapy
Matthew A. Hulverson et al.
JOURNAL OF INFECTIOUS DISEASES (2017)
Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR
Simon Planken et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Nitroimidazoles: Molecular Fireworks That Combat a Broad Spectrum of Infectious Diseases
Chee Wei Ang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Phase 1 Dose Escalation of PF-06747775 (EGFR-T790M Inhibitor) in Patients with Advanced EGFRm (Del 19 or L858R±T790M) NSCLC
Hatim Husain et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis
Melissa S. Love et al.
PLOS NEGLECTED TROPICAL DISEASES (2017)
Transcriptomic Profiling of High-Density Giardia Foci Encysting in the Murine Proximal Intestine
Jonathan K. Pham et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2017)
RNAi-Mediated Specific Gene Silencing as a Tool for the Discovery of New Drug Targets in Giardia lamblia; Evaluation Using the NADH Oxidase Gene
Jaime Marcial-Quino et al.
GENES (2017)
Novel Bumped Kinase Inhibitors Are Safe and Effective Therapeutics in the Calf Clinical Model for Cryptosporidiosis
Deborah A. Schaefer et al.
JOURNAL OF INFECTIOUS DISEASES (2016)
Identification and Validation of Small-Gatekeeper Kinases as Drug Targets in Giardia lamblia
Kelly M. Hennessey et al.
PLOS NEGLECTED TROPICAL DISEASES (2016)
Giardia duodenalis genetic assemblages and hosts
Martin F. Heyworth
PARASITE (2016)
Increased incidence of nitroimidazole-refractory giardiasis at the Hospital for Tropical Diseases, London: 2008-2013
L. E. B. Nabarro et al.
CLINICAL MICROBIOLOGY AND INFECTION (2015)
Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia
Marina Konopleva et al.
HAEMATOLOGICA (2015)
FDA-approved small-molecule kinase inhibitors
Peng Wu et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2015)
Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia
Marina Konopleva et al.
HAEMATOLOGICA (2015)
Development of potent and selective Plasmodium falciparum calcium-dependent protein kinase 4 (PfCDPK4) inhibitors that the transmission of malaria to mosquitoes
Rama Subba Rao Vidadala et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2014)
PDE inhibitors currently in early clinical trials for the treatment of asthma
Maria Gabriella Matera et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2014)
Neospora caninum Calcium-Dependent Protein Kinase 1 Is an Effective Drug Target for Neosporosis Therapy
Kayode K. Ojo et al.
PLOS ONE (2014)
Metabolism of nitro drugs metronidazole and nitazoxanide in Giardia lamblia: characterization of a novel nitroreductase (GlNR2)
Joachim Mueller et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2013)
The weight of nations: an estimation of adult human biomass
Sarah Catherine Walpole et al.
BMC PUBLIC HEALTH (2012)
Transmission of malaria to mosquitoes blocked by bumped kinase inhibitors
Kayode K. Ojo et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
High Prevalence of Giardia duodenalis Assemblage B Infection and Association with Underweight in Rwandan Children
Ralf Ignatius et al.
PLOS NEGLECTED TROPICAL DISEASES (2012)
High-Throughput Giardia lamblia Viability Assay Using Bioluminescent ATP Content Measurements
Catherine Z. Chen et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Variation in growth and drug susceptibility among Giardia duodenalis assemblages A, B and E in axenic in vitro culture and in the gerbil model
E. Benere et al.
PARASITOLOGY (2011)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Trypanosoma brucei Glycogen Synthase Kinase-3, A Target for Anti-Trypanosomal Drug Development: A Public-Private Partnership to Identify Novel Leads
Richard O. Oduor et al.
PLOS NEGLECTED TROPICAL DISEASES (2011)
The minimal kinome of Giardia lamblia illuminates early kinase evolution and unique parasite biology
Gerard Manning et al.
GENOME BIOLOGY (2011)
Metronidazole Is Still the Drug of Choice for Treatment of Anaerobic Infections
Sonja Lofmark et al.
CLINICAL INFECTIOUS DISEASES (2010)
Toxoplasma gondii calcium-dependent protein kinase 1 is a target for selective kinase inhibitors
Kayode K. Ojo et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2010)
Discovery of Potent and Selective Inhibitors of CDPK1 from C. parvum and T. gondii
Ryan C. Murphy et al.
ACS MEDICINAL CHEMISTRY LETTERS (2010)
Stable expression of Escherichia coli β-glucuronidase A (GusA) in Giardia lamblia: application to high-throughput drug susceptibility testing
Joachim Mueller et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
S Kobayashi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Variability and variation in drug susceptibility among Giardia duodenalis isolates and clones exposed to 5-nitroimidazoles and benzimidazoles in vitro
R Argüello-García et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2004)
分享论文
